Adarbi
Generic Name
Azilsartan Medoxomil
Manufacturer
Takeda Pharmaceutical Company Limited
Country
Japan (origin)
Loading images...
Price Details
Current market pricing information
| Variant | Unit Price | Strip Price |
|---|---|---|
| adarbi 80 mg tablet | ৳ 22.00 | ৳ 220.00 |
Description
Overview of the medicine
Azilsartan medoxomil is an angiotensin II receptor blocker (ARB) used to treat high blood pressure (hypertension). It helps relax blood vessels, allowing blood to flow more easily and reducing the workload on the heart.
Uses & Indications
Dosage
Adults
The usual starting dose is 40 mg once daily. The dose may be increased to 80 mg once daily after 1-2 weeks if further blood pressure reduction is needed.
Elderly
No initial dose adjustment is generally required, but close monitoring is recommended.
Renal_impairment
No initial dose adjustment is necessary for patients with mild to moderate renal impairment. For severe renal impairment, caution is advised, and lower doses may be considered with careful monitoring.
How to Take
Adarbi tablets are for oral administration. They can be taken with or without food. It is recommended to take the tablet at approximately the same time each day.
Mechanism of Action
Azilsartan medoxomil is a prodrug that is hydrolyzed to azilsartan, the active moiety. Azilsartan selectively blocks the binding of angiotensin II to the AT1 receptor in many tissues (e.g., vascular smooth muscle, adrenal gland), thereby inhibiting the vasoconstrictor and aldosterone-secreting effects of angiotensin II. This leads to vasodilation, decreased aldosterone secretion, and reduced blood pressure.
Pharmacokinetics
Onset
Blood pressure reduction is usually evident within 2 weeks, with the full effect observed within 2-4 weeks.
Excretion
Primarily excreted in feces (approximately 55%) and urine (approximately 42%) as metabolites and unchanged drug.
Half life
Approximately 11 hours (for azilsartan).
Absorption
Rapidly absorbed after oral administration. Peak plasma concentration (Cmax) is reached in 1.5 to 3 hours. Bioavailability is approximately 60%.
Metabolism
Metabolized by cytochrome P450 (CYP2C9) to two primary inactive metabolites.
Side Effects
Contraindications
- Hypersensitivity to azilsartan medoxomil or any component of the formulation.
- Concomitant use with aliskiren in patients with diabetes or renal impairment (GFR < 60 mL/min/1.73 m²).
- Pregnancy (especially during the second and third trimesters).
Drug Interactions
Lithium
Increased serum lithium concentrations and toxicity have been reported with concomitant use of ARBs.
Aliskiren
Concomitant use with aliskiren is contraindicated in patients with diabetes or moderate to severe renal impairment due to increased risk of hypotension, hyperkalemia, and renal impairment.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
NSAIDs may reduce the antihypertensive effect of ARBs and increase the risk of renal impairment, especially in dehydrated or elderly patients.
Potassium-Sparing Diuretics/Potassium Supplements
May lead to increased serum potassium levels (hyperkalemia).
Storage
Store at room temperature (20°C to 25°C), excursions permitted to 15°C to 30°C. Protect from moisture and light. Keep out of reach of children.
Overdose
Symptoms: The most likely manifestation of overdose is hypotension and possibly tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. Management: Supportive treatment should be initiated. If symptomatic hypotension occurs, place the patient in a supine position and administer intravenous saline infusion. Hemodialysis is unlikely to be effective for azilsartan or its metabolites.
Pregnancy & Lactation
Pregnancy: Contraindicated during the second and third trimesters of pregnancy due to the risk of fetal injury or death. Lactation: Not recommended. It is unknown whether azilsartan is excreted in human milk; however, other ARBs are known to be excreted. A decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Side Effects
Contraindications
- Hypersensitivity to azilsartan medoxomil or any component of the formulation.
- Concomitant use with aliskiren in patients with diabetes or renal impairment (GFR < 60 mL/min/1.73 m²).
- Pregnancy (especially during the second and third trimesters).
Drug Interactions
Lithium
Increased serum lithium concentrations and toxicity have been reported with concomitant use of ARBs.
Aliskiren
Concomitant use with aliskiren is contraindicated in patients with diabetes or moderate to severe renal impairment due to increased risk of hypotension, hyperkalemia, and renal impairment.
Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
NSAIDs may reduce the antihypertensive effect of ARBs and increase the risk of renal impairment, especially in dehydrated or elderly patients.
Potassium-Sparing Diuretics/Potassium Supplements
May lead to increased serum potassium levels (hyperkalemia).
Storage
Store at room temperature (20°C to 25°C), excursions permitted to 15°C to 30°C. Protect from moisture and light. Keep out of reach of children.
Overdose
Symptoms: The most likely manifestation of overdose is hypotension and possibly tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation. Management: Supportive treatment should be initiated. If symptomatic hypotension occurs, place the patient in a supine position and administer intravenous saline infusion. Hemodialysis is unlikely to be effective for azilsartan or its metabolites.
Pregnancy & Lactation
Pregnancy: Contraindicated during the second and third trimesters of pregnancy due to the risk of fetal injury or death. Lactation: Not recommended. It is unknown whether azilsartan is excreted in human milk; however, other ARBs are known to be excreted. A decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.
Frequently Asked Questions
Common questions about this medicine
Pack Sizes
Shelf Life
Typically 24 to 36 months from manufacturing date.
Availability
Pharmacies, Hospitals
Approval Status
FDA Approved
Patent Status
Patent Protected (original formulation)
Clinical Trials
Clinical trials have demonstrated that azilsartan medoxomil significantly lowers blood pressure and is generally well-tolerated compared to placebo and other ARBs in adult patients with hypertension.
Lab Monitoring
- Blood pressure monitoring
- Serum electrolytes (especially potassium)
- Renal function tests (serum creatinine, BUN)
Doctor Notes
- Assess renal function and serum potassium levels before initiating treatment and periodically thereafter, especially in patients with impaired renal function or those taking potassium-sparing diuretics.
- Advise female patients of childbearing age about the potential fetal harm and the need for effective contraception. Discontinue if pregnancy is confirmed.
- Counsel patients on signs of angioedema and to seek immediate medical attention if they occur.
Patient Guidelines
- Take Adarbi exactly as prescribed by your doctor, usually once daily.
- Do not stop taking Adarbi suddenly without consulting your doctor, as this may cause your blood pressure to rise.
- Inform your doctor immediately if you experience any symptoms of angioedema (e.g., swelling of the face, lips, tongue, or throat).
- Women of childbearing potential should use effective contraception while taking Adarbi and discontinue it immediately if pregnancy is detected.
Missed Dose Advice
If you miss a dose, take it as soon as you remember. If it is almost time for your next dose, skip the missed dose and continue your regular dosing schedule. Do not take a double dose to make up for a missed one.
Driving Precautions
Adarbi may cause dizziness or lightheadedness, especially when starting treatment or increasing the dose. If you experience these symptoms, avoid driving or operating machinery.
Lifestyle Advice
- Adopt a heart-healthy diet, low in sodium.
- Engage in regular physical activity as advised by your doctor.
- Limit alcohol consumption and avoid smoking.
- Manage stress effectively.
Alternative Medicines in Bangladesh
Similar medicines available in the market
Global Brand Names
International brand names for this medicine. Click a brand to search for detailed information.
Other Medicines in Adarbi Brand
Other medicines available under the same brand name
